Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Advanced Breast Cancer
Phase PHASE2
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SYS6023 — SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
  • Drug: KN026 — KN026 is an antibody targeting HER2, administered via intravenous infusion.

Primary Outcomes

  • The incidence of dose-limiting toxicity (DLT) (At the end of Cycle 1 (each cycle is 21 days).)
  • Frequency and severity of AEs and SAEs (according to NCI-CTCAE 6.0); (Baseline up to 28 days post last dose, Up to approximately 3 years)
  • Recommended Phase 2 Dose(RP2D) (Up to approximately 3 years)
  • Objective Response Rate (ORR) (Up to approximately 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-25
Completion: 2029-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Principal Investigators:
  • Qingyuan Zhang, M.D. (PRINCIPAL_INVESTIGATOR) - Affiliated Tumor Hospital of Harbin
Contact Information
Study Contact:
Clinical Trials Information Group officer
86-0311-69085587
ctr-contact@cspc.cn
Qingyuan Zhang, M.D.
86-13313612989
sy86298276@163.com
Qingyuan Zhang, M.D.
+86-13313612989
sy86298276@163.com
Affiliated Tumor Hospital of Harbin
Interventions
  • Drug: SYS6023 — SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
  • Drug: KN026 — KN026 is an antibody targeting HER2, administered via intravenous infusion.
Study Locations (1 sites)
Affiliated Tumor Hospital of Harbin, Harbin, Heilonjiang 150000 China
Eligibility Criteria
Inclusion Criteria: * 1\. Age ≥ 18 years old; * 2\. Histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer: * 3\. Sufficient tumor specimens must be provided for biomarker testing (human epidermal growth factor receptor 3-HER3), preferably obtained during or after the most recent treatment period; During safety run-in period, subjects who cannot provide sufficient tissue samples may be screened after sponsor's evaluation and approval; * 4\. Documented disease progression or intolerability with the most recent systemic anti-tumor treatment; * 5\. According to RECIST 1.1, at least one evaluable lesion (safety run-in period) or measurable lesion (cohort expansion phase); * 6\. ECOG PS score 0-1; * 7\. Expected survival ≥ 3 months; * 8\. Adequate organ function with laboratory tests meeting criteria (no blood transfusion or hematopoietic growth factor therapy within 14 days before testing): ANC ≥ 1.5 × 10\^9/L PLT ≥ 100 × 10\^9/L Hb ≥ 90 g/L TBIL ≤ 1.5 × ULN ALT, AST ≤ 2.5 × ULN; for participants with liver metastasis, ALT and AST ≤ 5 × ULN Creatinine clearance rate (Ccr) \> 35 mL/min (calculated according to Cockcroft-Gault formula) Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; International normalized ratio (INR) ≤ 1.5 × ULN Left ventricular ejection fraction (LVEF) ≥ 55% (only applicable to Cohort 2) * 9\. Eligible individuals with reproductive potential must agree to use reliable contraceptive methods (hormonal contraceptives, barrier methods, or abstinence) with their partners during the trial and for at least 7 months after the last dose; Women of childbearing potential must have a negative blood pregnancy test within 7 days before enrollment; * 10\. Fully understand this clinical trial and voluntarily sign the written informed consent form. Exclusion Criteria: * 1\. Prior treatment with HER3-targeted ADC therapy; * 2\. Applicable to Cohort 1: a. Prior treatment with any topoisomerase I inhibitor-loaded ADC therapy; b. Current presence or impending visceral crisis that has caused or may cause impending organ damage and/or other life-threatening complications; * 3\. Applicable to Cohort 2: a. Prior exposure to anthracyclines with cumulative dose exceeding 360 mg/m\^2doxorubicin equivalent; b. LVEF once dropped to \< 40% during prior anti-HER2 drug therapy, or symptomatic CHF occurred; * 4\. History of other malignancies within 3 years before randomization/first dose or concurrent active malignancies (except cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., which are allowed to enroll); * 5\. Untreated (including those detected during screening period) or unstable brain parenchymal metastasis, spinal cord metastasis or compression, carcinomatous meningitis. Subjects with treated stable brain metastases may be considered for enrollment (Note: refers to participants who have received local brain treatment, whose symptoms are stable, imaging tests show stability for at least 28 days before randomization/first dose, no evidence of progressive brain edema, and no need for glucocorticoids or other symptom control measures); * 6\. Adverse reactions from prior anti-tumor therapy have not recovered to CTCAE 6.0 grade ≤ 1 (except for toxicities such as alopecia that researchers judge to have no safety risk); * 7\. Major surgery within 28 days before randomization/first dose, or planned to undergo systemic or local tumor resection during the study period; * 8\. History of severe bleeding risk (e.g., gastrointestinal varices) or bleeding diathesis, any gastrointestinal bleeding or other bleeding of ≥ CTCAE grade 2 within 28 days before randomization/first dose; Abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months before randomization/first dose; * 9\. History of severe cardiovascular disease, including but not limited to: 1. Acute coronary syndrome within 6 months before randomization/first dose; 2. Stroke or transient ischemic attack within 6 months before randomization/first dose; 3. Pulmonary embolism or deep vein thrombosis within 3 months before randomization/first dose (intermuscular vein thrombosis may be enrolled if assessed as low risk by researchers); 4. CHF with NYHA functional classification ≥ II; 5. Documented history of cardiomyopathy that has not currently recovered; 6. Pericarditis; 7. Severe arrhythmia, such as ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, etc.; 8. Baseline average QTcF \> 450 ms (calculated using Fridericia formula), or history or family history of long QT syndrome; 9. Uncontrolled hypertension (defined as persistent systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg despite antihypertensive medication); * 10\. Presence of non-infectious lung disease/pneumonia requiring treatment at randomization/first dose, or history of interstitial lung disease/pneumonia requiring glucocorticoid treatment during prior anti-tumor therapy; * 11\. Active bacterial, fungal or viral infection within 14 days before randomization/first dose (defined as requiring intravenous anti-bacterial, anti-fungal or anti-viral drug therapy). Individuals receiving prophylactic anti-infective therapy without clinical manifestations of active infection may be considered for enrollment; * 12\. Active hepatitis B or hepatitis C, defined as HBsAg positive and HBV DNA \> 2000 IU/mL for active hepatitis B; defined as HCV-Ab positive and HCV RNA \> ULN for active hepatitis C; * 13\. History of immunodeficiency or positive HIV antibody test during screening; * 14\. Use of strong CYP3A4 inducers or inhibitors, OATP1B1 or OATP1B3 inhibitors before randomization/first dose (within 5 half-lives of inducer or inhibitor) or need to use such drugs during study treatment; * 15\. Known or suspected hypersensitivity to the study drug or its components; * 16\. Lactating women; * 17\. Presence of other conditions that may interfere with participants' participation in study procedures, not in line with participants' maximum benefit from participating in the study, or affect study results: such as history of mental illness, drug abuse or substance abuse, any other clinically significant disease or condition, etc.
Conditions Prostate Cancer (Adenocarcinoma)
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Semi-structured Interview — this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).

Primary Outcomes

  • Number and content of themes and subthemes describing PCa patients' perceptions of the risk of breast-related side effects, including gynaecomastia, from high-risk BCR PCa treatment. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-01
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: St Vincent's Hospital, Sydney
Collaborators: University of Technology, Sydney
Contact Information
Study Contact:
Anthony M Joshua, MBBS PhD
+61293555655
svhs.cancerresearch@svha.org.au
Kinghorn Cancer Centre
Interventions
  • Other: Semi-structured Interview — this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).
Study Locations (1 sites)
Kinghorn Cancer Centre, Sydney, New South Wales 2010 Australia
Eligibility Criteria
Inclusion Criteria: * Men with high-risk BCR PCa but no ADT+/-ARPI experience. * Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment. Exclusion Criteria: • Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.
Conditions Breast Cancer
Phase PHASE2
Enrollment 198
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the efficacy and safety of capecitabine as the only adjuvant chemotherapy drug in patients with low-risk early triple-negative breast cancer who have received adequate local treatment. Patients meeting the inclusion criteria will receive capecitabine metronomic therapy for one year.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine — Capecitabine 650mg/m2, bid, p.o for 1 year

Primary Outcomes

  • RFS (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-20
Completion: 2030-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 198 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin C Shao
02164175590
zhimingshao@yahoo.com
Yin Liu
02164175590
liuyinfudan@163.com
Zhimin Shao, MD
86-021-641755901105
zhimingshao@yahoo.com
breast cancer institute of Fudan University Shanghai Cancer Center
Interventions
  • Drug: Capecitabine — Capecitabine 650mg/m2, bid, p.o for 1 year
Study Locations (1 sites)
breast cancer institute of Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Male and female patients aged ≥18 years; 2. Pathological confirmed of stage I breast cancer: histologically confirmed that the longest diameter of invasive cancer is no more than 2cm and the lymph node is negative (N0); 3. Histologically documented TNBC after early breast cancer surgery (absence of HER2, ER, and PR expression) 4. Patients who have undergone standard and adequate surgical treatment; 5. Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute neutrophil count ≥ 1.5 x 109 /L; platelet count ≥ 100 \* 109 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN), Aspartate Aminotransferase (AST) ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum creatinine ≤ 1×ULN#and with endogenous creatinine clearance rate of \>50 ml/min (Cockcroft-Gault formula); 6. No evidence of metastasis in clinical or imaging examinations before surgery, that is, M0; 7. ECOG score of 0 or 1; 8. Meeting one of the low-risk criteria defined in this study: a) IM subtype, that is, the proportion of stromal tumor-infiltrating lymphocytes is high or CD8 is high; b) LAR subtype and ki-67 less than 20%; c) Age ≥ 70 years. 8)The patient voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up. Exclusion Criteria: 1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy; 2. Has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ; 3. Has metastic (Stage 4) breast cancer; 4. Pregnant or breast feeding women, or people of childbearing age who cannot practice effective contraceptives; 5. Patients participating in other clinical trials at the same time; 6. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \< 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\>150/90mmHg, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; Has severe or uncontrolled infection; 7) Has a history of psychotropic substance abuse and were unable to abandon drug habits, or those with history of mental disorders; 8)The researchers considered patients to be unsuitable for the study. 9)Has bilateral breast cancer
Conditions Breast Cancer
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

* Prospective, open-label, bi-center study, assessing the clinical outcomes of adaptive breast radiotherapy with ETHOS in hypersensitive patients. * Bi-centric with ETHOS center : ICM (Institut du Cancer de Montpellier) and ISC (Institut Sainte Catherine) Avignon * 500 patients will be included: * COHORTE A = Treatment ETHOS RT :46 evaluable patients with high risk of LRR and bf+ risk * COHORT B = Conventional IMRT : 454 others patients with high risk of LRR and bf- risk

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Treatment ETHOS radiotherapy — • Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
  • Radiation: Conventional IMRT — • Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin

Primary Outcomes

  • Rate of patients without any grade 2 and more toxicities within the planning target volume (at 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2030-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Principal Investigators:
  • BOURGIER CELINE (PRINCIPAL_INVESTIGATOR) - Institut du Cancer de Montpellier - Val d'Aurelle
  • ARNAUD ANTOINE (PRINCIPAL_INVESTIGATOR) - INSTITUT SAINTE CATHERINE / AVIGNON
Contact Information
Study Contact:
MOUSSION AURORE
0467613102
aurore.moussion@icm.unicancer.fr
Marc Ychou, MD, PhD
33-4-6761-3066
marc.ychou@icm.unicancer.fr
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Aurore MOUSSION
0467613102
aurore.moussion@icm.unicancer.fr
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Interventions
  • Radiation: Treatment ETHOS radiotherapy — • Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
  • Radiation: Conventional IMRT — • Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
Study Locations (1 sites)
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, 34298 France
Eligibility Criteria
Inclusion Criteria: * Women ≥ 18 years old. * Conservative breast cancer surgery or radical mastectomy. * At least pN1 breast cancers, regardless breast cancer subtypes. * Tumor negative margins. * Indication of whole breast and node irradiation. * Extension evaluation of disease will be proven negative (M0). * Risk level of breast fibrosis identified by the centralized NovaGray RILA Breast® test * Must be geographically accessible for follow-up. * Written and dated informed consent. * Affiliated to the French national social security system. Exclusion Criteria: * Patients with distant metastases. * Bilateral breast cancer (concomitant or prior) except in situ lesion, either ductal or lobular, of the contralateral breast. * Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years. * Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up. * Patients treated with systemic investigational drugs within the past 30 days (Observational cohorts are accepted if the collection of data does not interfere with the current trial) * Untreated hypothyroidism * Patients known to be HIV positive (no specific tests are required to determine the eligibility). * Patients known as hypersensitive to radiation (ATM Homozygote, p53-/-,…) * Pregnant or breast-feeding women * Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study * Person deprived of their liberty or under protective custody or guardianship.
Conditions Cancer of Head and Neck, Lung Cancer, No...
Phase Not Applicable
Enrollment 1650
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: OncoPrism™ assay — OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Primary Outcomes

  • PD-L1/PD-1 inhibitor response (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-02-05
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1650 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cofactor Genomics, Inc.
Collaborators: Curebase Inc.
Principal Investigators:
  • Jarret Glasscock (STUDY_DIRECTOR) - Cofactor Genomics
Contact Information
Study Contact:
Clinical Trial Coordinator
(888) 602-0448
clinicaltrials@cofactorgenomics.com
Study Director
(628) 200-4082
predapthelp@curebase.com
Curebase
Interventions
  • Diagnostic Test: OncoPrism™ assay — OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
Study Locations (1 sites)
Curebase, San Francisco, California 94131 United States
Eligibility Criteria
Inclusion Criteria: 1. Subject must have a disease of interest. Specifically, subject must have one of: 1. head and neck squamous cell carcinoma (HNSCC) 2. non-small-cell lung cancer (NSCLC) 3. small cell lung cancer (SCLC) 4. urothelial carcinoma (UCC) 5. gastric or gastroesophageal junction adenocarcinoma 6. cervical cancer 7. esophageal squamous cell carcinoma (ESCC) 8. triple-negative breast cancer (TNBC) 9. hepatocellular carcinoma (HCC) 10. renal cell carcinoma (RCC) 11. colorectal cancer (CRC) 2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1/PD-L1 immunotherapy for treatment of their cancer. 3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy. 4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy. 5. Willing to provide electronic informed consent per IRB-approved protocol. 6. Able to speak, read, and comprehend English fluently. 7. Subject is 18 years of age or older. 8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study. Exclusion Criteria: 1. Inability or unwillingness to provide informed consent. 2. Subject who does/did not have one of the cancers listed above (other histologies). 3. Subject has already participated in this trial.
Conditions Breast Cancer
Phase PHASE2
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cyclophosphamide — 60mg/m2 PO once a day (21 continuous days)
  • Drug: Methotrexate — 10mg/m2 PO BID on days 1, 8, and 15
  • Drug: Capecitabine — 825mg/m2 PO BID on days 1-14

Primary Outcomes

  • Relative Dose Intensity (RDI) in patients treated with the CMC regimen. RDI is defined as the sum total of delivered drug in mg/m2/week for each drug in the CMC regimen per the number of participants that have equal to or greater than 85% (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-22
Completion: 2034-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Contact Information
Study Contact:
Abiola Ibreeheem, MD
312-413-1581
abiolai@uic.edu
Prathmika Jha, BS
312-413-2746
pjha7@uic.edu
Abiola R Ibreeheem, MD
312-413-1581
abiolai@uic.edu
University of Illinois
Interventions
  • Drug: Cyclophosphamide — 60mg/m2 PO once a day (21 continuous days)
  • Drug: Methotrexate — 10mg/m2 PO BID on days 1, 8, and 15
  • Drug: Capecitabine — 825mg/m2 PO BID on days 1-14
Study Locations (1 sites)
University of Illinois, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria: I• Age ≥ 18 years of age at time of consent * ECOG performance status 0, 1, or 2 * Histologically confirmed invasive breast cancer documented by biopsy or surgical excision. * Underwent potentially curative resection of primary breast tumor(s) with no gross residual local-regional disease (patients with microscopically positive margins are eligible if adjuvant radiotherapy is planned), with most recent breast or axillary surgery \< 90 days prior to date of signed consent. * No evidence of distant metastatic disease * No prior systemic therapy for this cancer other than pre-operative endocrine therapy * Treating Oncologist recommends adjuvant chemotherapy without concurrent biologic/targeted therapy. Patients may receive a CDK4/6 inhibitor after completion of all study treatment, concurrently with adjuvant endocrine therapy. Patients with a germline pathogenic/likely pathogenic variant in a DNA homologous repair gene (e.g. BRCA1, BRCA2, PALB2) may receive adjuvant PARP inhibitor therapy after completion of all study treatment. * Tumor is estrogen receptor (ER)-positive (\> 10% by IHC) and/or progesterone receptor (PR)-positive (\> 10% by IHC), HER2-negative by IHC or FISH according to 2018 ASCO-CAP guidelines. * AJCC pathologic stage: o pT1-3/pN0-2 based on sentinel lymph node biopsy or axillary dissection * High risk gene expression profile (either luminal B on MammaPrint/BluePrint, or Recurrence Score \> 25 on Oncotype Dx). Study participants are not required to have a high-risk gene expression profile if they have a clinical high-risk tumor, defined as: Age \< 50 and any of the following: * Involvement of 1-3 axillary lymph nodes with metastatic carcinoma (pN1mic/N1) * grade 1 tumor \> 3 cm; or grade 2 tumor \> 2 cm; or grade 3 tumors \> 1 cm (size based on pathological assessment of the maximal dimension of the invasive component of the tumor) * pT1c-T2 and Ki-67 \> 20% * Presence of lymphovascular invasion stage IIIA (pT3/pN1 or pT1-3/pN2) Age \> 50 and any of the following: * Primary tumor \> 5 cm (pT3) * stage IIIA (pT3/pN1 or pT1-3/pN2) * Adequate organ function as defined in Table 1. All screening labs to be obtained within 30 days prior to registration. * Patients with synchronous bilateral primary breast tumors or multiple ipsilateral primary breast tumors are eligible if the treating Oncologist determines that the CMC regimen is appropriate therapy for all primary tumors requiring chemotherapy. * Able to provide written informed consent and HIPAA authorization for release of personal health information. * Women of childbearing potential must agree to use 2 methods of birth control, at least one being a barrier form of contraception if they are sexually active with a male partner unless they are considered highly unlikely to conceive as defined in section 8.6, and cannot be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. * As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. * Patients with history of HIV/AIDS (acquired immunodeficiency syndrome) are eligible for this study if they are receiving anti-retroviral therapy and it does not include any medications known to alter metabolism or tolerability of component drugs in the CMC regimen (see Appendix), and either of the following criteria are met: * Patients without a history of AIDS-defining opportunistic infections. * Patients with a history of AIDS-defining opportunistic infections, but they have not had an opportunistic infection within the past 12 months. * Patients with Hepatitis B (HBV): chronic carriers of HBV infection (HBsAg-positive) or individuals who have serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and anti-HBc-positive) are eligible if they are receiving appropriate suppressive antiviral therapy that does not include medications known to alter metabolism or tolerability of component drugs in CMC (see Appendix) prior to initiation of cancer therapy, and liver function tests meet study eligibility criteria. * Patients with Hepatitis C (HCV): patients with a history of HCV infection who have completed curative antiviral treatment are eligible if the HCV RNA viral load is below the limit of quantification within 90 days of study enrollment. Patients on concurrent HCV treatment must have HCV RNA viral load below the limit of quantification within 30 days of study enrollment. Patients must also meet liver function test eligibility requirements and antiviral therapy does not include medications known to alter metabolism or tolerability of component drugs in CMC. Exclusion Criteria Subjects meeting any of the criteria below are ineligible for this study: * Prior cytotoxic chemotherapy for this breast cancer * Any investigational agents administered during or within 2 weeks prior to start of CMC chemotherapy * AJCC stage IIIB-IIIC or stage IV * Active infection requiring systemic therapy * Untreated HIV/AIDS * Documented DYPD deficiency * Pregnant or nursing * Require anticoagulation with warfarin. Anticoagulation with low molecular weight heparins, heparin, or direct oral anticoagulants (DOACs) is permitted. * Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist. * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial. * Other major comorbidity (e.g. advanced cardiopulmonary disease, uncontrolled diabetes mellitus) that may affect the safety or efficacy assessment of this investigational regimen, as determined by study PI * Inability to swallow pills * Any medical condition interfering with absorption of oral medications * Any contraindication for any chemotherapy drug used in the CMC regimen * Active and ongoing use of medicines known to alter metabolism or tolerability of component drugs in CMC. * Prisoners * Unable or unwilling to take a large number of oral pills
Conditions Breast Cancer, Prostate Cancer, Brain Tu...
Phase EARLY_PHASE1
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: 68Ga-RM26-RGD — Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
  • Drug: 18F-FDG — 18F-FDG injection
  • Drug: 68Ga-RM26 — Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
  • Drug: 68Ga-RGD — Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

Primary Outcomes

  • Diagnostic performance1 (through study completion, an average of 1 year)
  • Diagnostic performance2 (through study completion, an average of 1 year)
  • Diagnostic performance3 (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2022-08-16
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Principal Investigators:
  • Zhaohui Zhu, MD,PHD (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital
Contact Information
Study Contact:
Zhaohui Zhu, MD,PHD
86+13611093752
13611093752@163.com
Zhaohui Zhu, MD,PHD
86+19800370331
pumch_jacobwong@163.com
Zhaohui Zhu, MD,PHD
86+13611093752
13611093752@163.com
Peking Union Medical College Hospital
Interventions
  • Drug: 68Ga-RM26-RGD — Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
  • Drug: 18F-FDG — 18F-FDG injection
  • Drug: 68Ga-RM26 — Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
  • Drug: 68Ga-RGD — Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study Locations (1 sites)
Peking Union Medical College Hospital, Beijing, China
Eligibility Criteria
Inclusion Criteria: * patients with confirmed or suspected breast/brain/prostate cancer; * 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Conditions Cancer
Phase Not Applicable
Enrollment 15000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Genetic: KRAS-variant and microRNA binding site mutation testing — Participant in these studies will be tested for the KRAS-variant

Primary Outcomes

  • Measuring the prevalence of the KRAS-variant in certain populations Prevalence of the KRAS-variant in BRCA negative breast cancer patients (1 year)
  • Comparing the impact of interventions in KRAS-variant versus non-KRAS variant populations (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2014-09
Completion: 2035-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 15000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MiraKind
Principal Investigators:
  • Joanne Weidhaas, MDPhD (PRINCIPAL_INVESTIGATOR) - MiraKind
Contact Information
Study Contact:
Joanne Weidhaas, MDPhD
203-671-1308
joanne@mirakind.org
Joanne Weidhaas
424-387-8100
Joanne@miradx.com
Joanne Weidhaas, MDPhD
203-671-1308
joanne@mirakind.org
MiraKind
Interventions
  • Genetic: KRAS-variant and microRNA binding site mutation testing — Participant in these studies will be tested for the KRAS-variant
Study Locations (1 sites)
MiraKind, Los Angeles, California 90025 United States
Eligibility Criteria
Inclusion Criteria: * Personal or family history of cancer * Personal history of endometriosis, or autoimmunity Exclusion Criteria: * Younger than 18 * Non-english speaking and unable to understand and sign the consent
Conditions Colorectal Cancer, Esophagus Cancer, Gas...
Phase PHASE1
Enrollment 30
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA positive late malignant solid tumors, and explore the applicable dose regimen for phase II clinical trials.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: CEA-targeted CAR-T cells — Administration method: intravenous infusion; Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Primary Outcomes

  • To determine the dose range and DLT of C-13-60 cells for CEA positive advanced malignant solid tumors [Safety and Tolerability] (1 month)
  • To obtain the maximum tolerable dose of C-13-60 cells [Safety and Tolerability] (1month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-08-11
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chongqing Precision Biotech Co., Ltd
Collaborators: Zhejiang University
Principal Investigators:
  • Ying Yuan, M.D (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital, Zhejiang University, School of Medicine
  • Weijia Fang, M.D (PRINCIPAL_INVESTIGATOR) - Zhejiang University
Contact Information
Study Contact:
Ying Yuan, M.D
13858193601
yuanying1999@tom.com
Weijia Fang, M.D
13758211655
weijiafang@zju.edu.cn
Weijia Fang, MD
13758211655
weijiafang@zju.edu.cn
The First Affiliated Hospital of Zhejiang University School of Medicine
Interventions
  • Biological: CEA-targeted CAR-T cells — Administration method: intravenous infusion; Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
Study Locations (2 sites)
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old, male or female; 2. Patients with advanced malignant solid tumors confirmed by histology or pathology, including colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, and cholangiocarcinoma; 3. Progression or intolerance occurs after receiving systematic standard therapy according to guidelines,(systemic therapy including but not limited to systemic chemotherapy, molecular targeting, etc.) and is not suitable for surgery or local therapy (including ablative therapy, interventional therapy, and radiation therapy), among which colorectal cancer needs to receive at least third-line therapy failure or intolerance or inapplicability. Esophageal, gastric, non-small cell lung, breast, and cholangiocarcinoma require at least second-line treatment failure or intolerance or inadequacy, and pancreatic cancer require at least first-line treatment failure or intolerance or inadequacy: 1. Advanced colorectal cancer: progression or intolerance or inadequacy after third-line standard therapy including cetuximab ± Irinotecan/regorafenib /fruquintinib/trifluridine; 2. Advanced or metastatic esophageal cancer/esophagogastric junction cancer: patients with esophageal cancer who progress or are intolerant or inapplicable after second-line therapy including PD-1 MAB /PD-L1 mab; Patients with esophagogastric junction cancer progressed or were intolerant or inapplicable after second-line therapy including taxane or irinotecan or PD-1 /PD-L1 monoclonal antibody; For HER-2 positive patients, trastuzumab containing system therapy should fail or be intolerable or not applicable; 3. Advanced/metastatic gastric cancer: the combination of PD-1 MAB /PD-L1 MAB and chemotherapy has been developed or is not tolerated or suitable; For HER-2 positive patients, systemic treatment containing trastuzumab should fail or be intolerable or inapplicable. 4. Patients with advanced, metastatic, or recurrent non-small cell lung cancer who have received systemic treatment progression or intolerance, including: Patients with positive driver genes (EGFR, ALK, ROS1, BRAF, NTRK, MET, RET) should receive targeted therapy failure or drug resistance (squamous cell carcinoma does not require driver gene testing). In addition, patients with EGFR-positive driver gene who are resistant to first-line EGFR-Tkis and who are positive for EGFR T790M mutations need to be treated with third-generation EGFR-TKI (such as Osimertinib, almonertinib, or furmonertinib) after failure or resistance. For patients with positive ALK fusion and drug resistance after first-line crizotinib treatment, second-line treatment with ceritinib or alectinib should fail or be resistant; Patients with PD-L1 expression (PD-L1 TPS≥1%) should undergo immune checkpoint inhibitor treatment failure or intolerance; In patients with negative driver genes, the disease progresses or becomes intolerable after chemotherapy with platinum-containing regiments-such as Camrelizumab, Pembrolizumab, Tislelizumab, Sintilimab or Atezolizumab combined with pemetrexed 5. Advanced, metastatic breast cancer: HER-2 positive patients need to have received anti-HER-2 therapy, hormone receptor positive patients need to receive endocrine therapy and other standard treatments have failed or are intolerable or not applicable, and rescue chemotherapy for those who have failed/are intolerable or triple-negative breast cancer (including: Gemcitabine + cisplatin/carboplatin, albumin paclitaxel/other taxoid drugs + cisplatin/carboplatin) fail or are not tolerated or suitable; 6. Locally advanced or metastatic pancreatic cancer: advanced or intolerant or inappropriate after at least first-line treatment, including: Gemcitabine + albumin-bound paclitaxel/cisplatin/erlotinib/capecitabine/tegafur/Nimotuzumab, or FOLFIRINOX (oxaliplatin + irinotecan +LV+5-FU), or mFOLFIRINOX (oxaliplatin + irinotecan + calcium folinate +5-FU); 7. Advanced cholangiocarcinoma: progression or intolerance or inapplicability after at least second-line therapy (mFOLFOX); Remarks: Chemotherapy failure is defined as disease progression or intolerable toxicity during treatment or within 3 months after the last dose; If patients cannot receive the above treatment for economic reasons, those whose benefits outweigh the risks of inclusion in the study can be enrolled. 4. Subjects with positive CEA (IHC score 3+) in tumor tissue samples (paraffin sections or fresh tissue specimens or puncture biopsy samples) within 3 months before screening; If the immunohistochemical results of the tumor samples are more than 3 months from the time of screening, the patient needs to re-biopsy; If the tumor specimens are not available or the amount is too small for immunohistochemical detection of CEA, the CEA positive can be confirmed by re-staining of previous tissue specimens, and the peripheral blood serum CEA≥2.0×ULN can be included in the group. 5. Have at least one evaluable target lesion according to RECIST 1.1 criteria; 6. Colorectal cancer, esophageal cancer, non-small cell lung cancer, breast cancer, stomach cancer, cholangiocarcinoma ECOG 0 \~ 1 score, pancreatic cancer ECOG 0 \~ 2 score; 7. Expected survival time is more than 12 weeks; 8. No serious mental disorders; 9. Unless otherwise stated, the subject's vital organ functions shall meet the following conditions: 1. Blood routine: white blood cells \> 3.5×109/L, neutrophils \> 1.8×109/L, lymphocytes \&gt; 0.5 ×109/L, platelet \> 80×109/L, hemoglobin \> 90g/L; 2. Cardiac function: Echocardiography indicated cardiac ejection fraction ≥50%, and no obvious abnormality was found in electrocardiogram; 3. Renal function: serum creatinine ≤2.0×ULN; 4. Liver function: ALT and AST≤3.0×ULN (patients with liver tumor infiltration can be relaxed to ≤5.0 ×ULN); 5. Total bilirubin ≤2.0×ULN (Gilbert syndrome ≤3.0×ULN; The patients with liver tumor infiltration can be enlarged to ≤5.0×ULN); 6. Blood oxygen saturation in non-oxygen state \&gt; 92%. 10. Have the criteria for simple or intravenous blood collection, and no other contraindications for cell collection; 11. The subject agrees to use a reliable and effective method of contraception (excluding safe period contraception) for 1 year from signing the informed consent to receiving the C-13-60 cell infusion. Including but not limited to: abstinence, can inhibit ovulation implantable progesterone contraceptive; Intrauterine device (IUD); Intrauterine hormone release system; Spousal vasectomy; Combined hormonal contraceptives (oral, vaginal, and transdermal) that inhibit ovulation; Progesterone contraceptives (oral or injectable) that inhibit ovulation; Male subjects who have sex with fertile women must consent to the use of a barrier method of contraception (e.g., condom plus spermicidal foam/gel/film/emulsion/suppository). At the same time, the subject should promise not to donate eggs (egg cells, oocytes) or sperm for assisted reproduction within 1 year after the cell infusion. 12. The patient or his/her guardian agrees to participate in the clinical trial and signs the ICF, indicating that he/she understands the purpose and procedure of the clinical trial and is willing to participate in the study. Exclusion Criteria: 1. People who have received CAR-T therapy or other gene-modified cell therapy; 2. Patients with BMS with clinical symptoms or lesions located in key parts of the brain at the time of screening, patients with BMS without clinical symptoms or lesions located in non-critical parts of the brain should be evaluated by researchers or specialists to gain more than the risk. 3. Received any of the following medications or treatments before screening: 1. Received other investigational drugs or treatments that are not on the market within 4 weeks prior to screening; 2. Received live attenuated vaccine within 4 weeks prior to screening; 3. Received radioactive i
Conditions Ovarian Cancer, Breast Cancer, Pancreati...
Phase PHASE1
Enrollment 318
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HS-10502 — HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.

Primary Outcomes

  • Maximum tolerated dose (MTD) of HS-10502(Stage 1) (Cycle 1 (28 days))
  • Maximum applicable dose (MAD) of HS-10502(Stage 1) (Cycle 1 (28 days))
  • Efficacy of HS-10502: Objective response rate (ORR)(Stage 2) (From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-06-09
Completion: 2026-10-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 318 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Lingying Wu, Medical PhD
13910865483
wulingying@csco.org.cn
Da Wei Wu
Cancer Hospital Chinese Acedemy of Medical Sciences
Interventions
  • Drug: HS-10502 — HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.
Study Locations (1 sites)
Cancer Hospital Chinese Acedemy of Medical Sciences, Beijing, Beijing Municipality 100020 China
Eligibility Criteria
Inclusion Criteria: 1. Males or females aged 18 - 75 years (inclusive). 2. Having at least one target lesion per the RECIST v1.1. 3. For the phase Ia Cohort A: advanced solid tumor carrying HRR gene mutation with failure or intolerance or not available to the currently available Standard of care (SoC). 4. For the phase Ib study: Cohort B: patients with HRD positive recurrent ovarian cancer with failure or intolerance or not available to SoC Cohort C: patients with HRR gene mutation advanced Human epidermal growth factor receptor 2 (HER2)-negative breast cancer with failure or intolerance or not available to SoC Cohort D: patients with HRR gene mutation advanced pancreatic cancer with failure or intolerance or not available to SoC Cohort E: patients with HRR gene mutation mCRPC with failure or intolerance or not available to SoC Cohort F: patients with HRR gene mutation colorectal cancer with failure or intolerance or not available to SoC Cohort G: patients with other HRR gene mutation or HRD positive advanced solid tumors with failure or intolerance or not available to SoC 5. Eastern cooperative oncology group (ECOG) performance status was 0-1. 6. Minimum life expectancy \> 12 weeks. 7. Females should be using adequate contraceptive measures and should not be breastfeeding Males should be using adequate contraceptive measures. 8. Have signed Informed Consent Form. Exclusion Criteria: 1. Received or are receiving the following treatments: 1. Previous or current treatment with two or more Poly(ADP-ribose) polymerase (PARP) inhibitors. 2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment. 3. Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment; Nitrosourea or Mitomycin C within 6 weeks prior to the first dose of study treatment. 4. Local radiotherapy within 2 weeks prior to the first dose of study treatment; more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment. 5. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion. 6. Major surgery within 4 weeks prior to the first dose of study treatment. 2. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy. 3. History of other primary malignancies. 4. Known and untreated, or active central nervous system metastases. 5. Inadequate bone marrow reserve or hepatic and renal functions. 6. Myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), or with features suggestive of MDS or AML. 7. Severe, uncontrolled or active cardiovascular disorders. 8. Diabetic ketoacidosis or hyperosmolar hyperglycemic state within 6 months prior to the first dose of study treatment; glycosylated hemoglobin ≥ 7.5%. 9. Serious or poorly controlled hypertension. 10. Any life-threatening hemorrhagic event or events requiring blood transfusion within 120 days prior to the first dose of study treatment. Clinically significant hemorrhagic symptoms or obvious hemorrhagic tendency. 11. Serious infection within 4 weeks prior to the first dose of study treatment, or presence of uncontrollable active infection in the screening period. 12. Having serious neurological or mental disorders. 13. A history of hypersensitivity to any of the active or inactive ingredients of HS-10502 or drugs with a similar chemical structure to HS-10502 or in the same class as HS-10502. 14. Patients who may have poor compliance with the procedures and requirements of the study, as judged by the investigator. 15. Patients with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.
Conditions Triple Negative Breast Cancer, Nab-pacli...
Phase PHASE2
Enrollment 414
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease. The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Nab-paclitaxel + Carboplatin — nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
  • Drug: Nab-paclitaxel + Capecitabine — Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles;

Primary Outcomes

  • Progression free survival (PFS) (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2019-11-20
Completion: 2028-09-20
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 414 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hebei Medical University Fourth Hospital
Collaborators: Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Principal Investigators:
  • Zefei Jiang, M.D. (STUDY_CHAIR) - Beijing 302 Hospital
  • Cuizhi Geng, M.D. (STUDY_CHAIR) - Hebei Medical University Fourth Hospital
Contact Information
Study Contact:
Cuizhi Geng, M.D.
0311-6669 6310
gengcuizhi@hotmail.com
Cuizhi Geng, M.D.
0311-6669 6310
gengcuizhi@hotmail.com
The Fourth Hospital of Hebei Medical University
Interventions
  • Drug: Nab-paclitaxel + Carboplatin — nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
  • Drug: Nab-paclitaxel + Capecitabine — Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles;
Study Locations (1 sites)
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011 China
Eligibility Criteria
Inclusion Criteria: 1. Females with age between 18 to 70 years old; 2. Histologically confirmed triple negative breast cancer; 3. No more than one-line prior treatment for locally advanced or metastatic breast cancer; 4. Have at least one measurable lesion as per the RECIST criteria (version 1.1); 5. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to one; 6. Patients with life expectancy of at least 3 months; 7. Bone marrow function:neutrophils (≥1.5×10\^9/L), platelets (≥100×10\^9/L), hemoglobin (≥90 g/L); 8. Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert's syndrome ≤ 2.5 × ULN; 9. Patients had good compliance with the planned treatment, understood the research process and written informed consent. Exclusion Criteria: 1. Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores; 2. Brain metastasis; 3. Recurrence or metastasis within 6 months after capecitabine withdrawal; 4. Recurrence or metastasis within 6 months after platinum withdrawal; 5. Progression in the treatment, recurrence or metastasis of paclitaxel (including albumin paclitaxel) within 6 months; 6. Patients required clinical intervention with gastrointestinal bleeding, gastrointestinal obstruction and non-feeding; 7. Patients who had Grade 2 or above Peripheral neuropathy; 8. Patients with severe systemic infection or other serious diseases; 9. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants; 10. Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer; 11. Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial; 12. Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given; 13. The researchers considered the patients who were not suitable for enrollment.
Conditions Breast Cancer Stage IV
Phase PHASE2
Enrollment 50
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, single arm, non-randomized, multicenter phase II study for the identification of predictive biomarkers of sacituzumab govitecan benefit and the understanding of key resistance mechanisms in HR+/HER2- advanced/metastatic breast cancer patients

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab Govitecan — Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle

Primary Outcomes

  • CelTIL score (baseline and at Cycle 2 Day 1 (14-21 days after treatment initiation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-15
Completion: 2027-02-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SOLTI Breast Cancer Research Group
Principal Investigators:
  • Eva Ciruelos, MD (PRINCIPAL_INVESTIGATOR) - Hospital 12 de Octubre, Madrid/SOLTI
  • Mafalda Oliveira, MD (PRINCIPAL_INVESTIGATOR) - Hospital Vall d'Hebrón/SOLTI
Contact Information
Study Contact:
Mariana Paes Dias, PhD
0034 609 384 751
mariana.paes@gruposolti.org
Fernando Salvador, PhD
0034 616 194 478
fernando.salvador@gruposolti.org
Angelica Ferrando, MD
ICO Badalona
Interventions
  • Drug: Sacituzumab Govitecan — Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
Study Locations (10 sites)
ICO Badalona, Badalona, Barcelona 08916 Spain
ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona 08907 Spain
Hospital Universitari Vall d'Hebrón, Barcelona, 08035 Spain
Hospital Clínic de Barcelona, Barcelona, 08036 Spain
HU Clínico San Cecilio, Granada, 18016 Spain
Fundación Jiménez Díaz, Madrid, 28040 Spain
Hospital Universitario 12 de Octubre, Madrid, 28041 Spain
Hospital Sant Joan de Reus, Reus, 43204 Spain
Hospital Universitario Virgen del Rocio, Seville, 41013 Spain
Hospital Clínico de Valencia, Valencia, 46010 Spain
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses. 2. Patients must be male or female (pre/peri or postmenopausal) ≥ 18 years of age. 3. ECOG performance status of 0 or 1(see Appendix 1). 4. Histologically or cytologically confirmed breast cancer with evidence of locally advanced disease, not amenable to resection or radiation therapy with curative intent or metastatic disease. 5. HR+/HER2- BC by local testing, not amenable to surgical therapy will be enrolled in this study. 1. HER2 negativity is defined as either of the following by local laboratory assessment: IHC 0, IHC 1+ or IHC2+/in situ hybridization (ISH) negative as per the most recent American Society of Clinical Oncology (ASCO)-College of American Pathologists Guideline (CAP) guideline. If a patient has had multiple HER2 results after metastatic disease, the most recent test result prior screening period will be used to confirm eligibility. 2. ER and/or PR positivity are defined as \>1% of cells expressing HR via IHC analysis as per most recent ASCO-CAP guideline. If a patient has had multiple ER/PgR results after metastatic disease, the most recent test result prior screening period will be used to confirm eligibility. 6. Disease refractory to CDK4/6 inhibitors, defined as recurrence during or within 12 months after the end of adjuvant treatment or progression during or within 6 months after the end of treatment for advanced/metastatic disease. 7. No more than 1 prior systemic chemotherapy or antibody-drug conjugate (ADC) regimens for metastatic disease. Adjuvant or neoadjuvant therapy for early-stage disease will qualify as one of the required prior chemotherapy regimens if the development of unresectable, locally advanced, or metastatic disease occurred within a 12-month period of time of the therapy. Note: treatments for bone metastases (eg, bisphosphonates, denosumab, etc.), targeted therapies (eg, PARP inhibitors, CDK 4/6 inhibitors, immunotherapy etc.) and hormonal therapy are not considered as prior systemic chemotherapy treatments for advanced disease. 8. Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting study treatment 9. Measurable or non-measurable disease but evaluable (identification of target and/or non-target lesions by RECIST Vs1.1). 10. Patients must have a site of disease amenable to safely perform a biopsy, as per Investigator's assessment, and be a candidate for tumor biopsy according to the treating institution's guidelines. 11. Possibility of performing a biopsy prior to the start of treatment and its repetition after 2 weeks (14-21 days) and at End of Treatment (EOT) on the same location. It will be provided formalin-fixed paraffin-embedded (FFPE) tumor block. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for quality prior to enrollment. Patients whose tumor tissue is not evaluable for central testing are not eligible. It is recommended to send the biopsy directly to the central lab after confirming the existence of a tumor, so as not to delay the inclusion, without the need to carry out IHC studies in the same sample. * Acceptable samples include core needle biopsies for deep tumor tissue or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, bone or mucosal lesions or biopsies from bone metastases. Lymph node biopsies are also permitted. * Fine needle aspiration, brushing, cell pellet from pleural effusion and lavage samples are not acceptable. 12. Patients must have normal organ and bone marrow function measured within 35 days prior to administration of study treatment as defined below: * Haemoglobin ≥ 9.0 g/dL \* * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L\* * Platelet count ≥ 100 x 109/L\* * Total bilirubin (TBL) ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia). * AST (SGOT) / ALT (SGPT) ≤ 2.5 x ULN unless liver metastases are present in which case, they must be ≤ 5x ULN * Creatinine ≤ 1.5 x ULN or Creatinine clearance estimated of ≥30mL/min using the Cockcroft-Gault equation. * Serum albumin \>3 g/dL * International normalized ratio (INR) or prothrombin time (PT) and either partial thromboplastin or activated partial thromboplastin time (aPTT) ≤ 1.5 ×ULN \*Without transfusional or growth factor support within 1 week of study treatment initiation. 13. Patients must have a life expectancy ≥ 16 weeks. 14. Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described in Appendix 2. 15. Willing and able to comply with the requirements and restrictions in this protocol. Exclusion Criteria: 1. Patients with HER2-positive or TNBC disease. 2. Other malignancy unless curatively treated with no evidence of disease for ≥3 years except: non-melanoma skin cancer, in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma or other malignant tumors with an expected curative outcome after medical monitor approval. 3. Has unresolved toxicities from previous anticancer therapy (≥ CTCAE version 5.0 grade 1) caused by previous cancer therapy, excluding alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to ≥Grade 2 for at least 2 months prior to enrollment and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, such as: Chemotherapy-induced neuropathy, Fatigue, Residual toxicities from prior IO treatment Grade 1 or Grade 2 endocrinopathies. Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. 4. Patients may not be participating in a study with an investigational agent or investigational device within 2 weeks or 5 half-lives, whichever is longer, prior to allocation. Patients participating in observational studies are eligible. 5. Patients with symptomatic uncontrolled brain metastases. Participants with a history of treated Central Nervous System (CNS) metastases are eligible, provided they meet all of the following criteria: * Biopsiable disease outside the CNS is present. * No evidence of interim CNS progression between the completion of CNS directed therapy and the screening radiographic study. * Metastases are limited solely to cerebellar and supratentorial lesions. * Stable requirement for corticosteroids (≤ 20 mg oral prednisone or equivalent) or anticonvulsants during \>4 weeks as therapy for CNS disease. * No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to enrolment. * No evidence of progression or haemorrhage after completion of CNS directed therapy. * Patients with spinal cord compression are excluded unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days. 6. History of significant cardiovascular disease, defined as: * New York Heart Association Class III or greater congestive heart failure or known left ventricular ejection fraction of \< 40%. * Unstable angina or myocardial infarction within 6 months before enrolment. * History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation. 7. Have active chronic inflamma